



**pharma& to Highlight Post-Progression Data for Rubraca® (rucaparib) in HRD-Negative and HRD-Unknown Advanced Ovarian Cancer at ESGO Congress 2026**

*Intended for the healthcare media*

**Vienna, Austria, February 17, 2026** – pharmaand GmbH (pharma&), a global company dedicated to preserving the availability and fostering the further development of essential medicines to leave no patient behind, today announced post-progression data for Rubraca® (rucaparib) in advanced ovarian cancer will be presented in a poster session during the **European Society of Gynaecological Oncology (ESGO)'s 27th European Gynaecological Oncology Congress** taking place Feb. 26 – 28 in Copenhagen, Denmark.

**Abstract No. 635:** Rucaparib maintenance in ATHENA-MONO (GOG3020/ENGOT-ov45) in patients with newly diagnosed advanced ovarian cancer: exploratory post-progression evaluations for patients with homologous recombination deficiency (HRD)-negative and HRD-unknown tumors

**Presenter:** Dr. Vanda Salutari, Department of Health of Women and Child, Catholic University of Sacred Heart, Rome, Italy

**Lead Author:** Dr. Flora Zagouri, Aretaieio Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece

**Time and Date:** 5:20 p.m. CEST, Friday, February 27

**Poster Number:** P06-23

**Location:** Bella Center Exhibition Hall

pharma& has also organized and funded a medical symposium, "PARP Inhibitors in Advanced Ovarian Cancer, Expanding Horizons: Transforming Outcomes and Supporting Patients to Move Forward."

**Presenters:**

- Prof. Domenica Lorusso, Humanitas Hospital San Pio X, Humanitas University, Milan, Italy
- Dr. Rebecca Kristeleit, Guy's and St Thomas' NHS Foundation Trust, London, UK
- Dr. Vanda Salutari, Department of Health of Women and Child, Catholic University of Sacred Heart, Rome, Italy
- Prof. Jalid Sehoul, Department of Gynecology, Charité Universitätsmedizin, Berlin, Germany
- Robin Lyn Gooch, Patient and Representative, German Ovarian Cancer Foundation

**Time and Date:** 11:00 a.m. CEST, Friday, February 27

**Location:** Bella Center Session Hall 3

Attendees can **visit pharma& at booth 01**, in **Hall D3** of the Bella Center Copenhagen.

## **About the ATHENA Clinical Trial**

ATHENA (GOG 3020/ENGOT-ov45) ([NCT03522246](https://clinicaltrials.gov/ct2/show/study/NCT03522246)) is an international, randomized, double-blind, phase III trial consisting of two separate and fully independently powered study comparisons evaluating rucaparib monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment for patients with newly diagnosed advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. ATHENA enrolled approximately 1000 patients across 24 countries, all women with newly diagnosed ovarian cancer who responded to their first-line chemotherapy. The trial completed accrual in 2020 and was conducted in association with the GOG Foundation, Inc. (GOG-F) in the U.S. and the European Network of Gynaecological Oncological Trial groups (ENGOT) in Europe. GOG-F and ENGOT are the two largest cooperative groups in the U.S. and Europe dedicated to the treatment of gynecological cancers.

ATHENA-MONO is evaluating the benefit of rucaparib monotherapy versus placebo in 538 women in this patient population. The primary efficacy analysis evaluated two prospectively defined molecular sub-groups in a step-down manner: 1) HRD-positive (inclusive of BRCA mutant) tumors, and 2) the intent-to-treat population, or all patients treated in ATHENA-MONO.

###

## **About pharma& ([pharmaand.com](https://pharmaand.com))**

pharmaand GmbH (pharma&), a privately owned global company, aspires to breathe new life into proven medicines. The Company is dedicated to preserving the availability and fostering the further development of essential medicines worldwide to leave no patient behind. Since its inception, pharma& has acquired and integrated 10+ medicines, expanding its portfolio across a wide range of therapy areas, with an increasing focus on hematology and oncology treatments. The Company's unique synthesis of subsidiaries, joint ventures, and partners enables pharma& to provide its portfolio of medicines to eligible patients worldwide by spanning the continuum of research and development, in-house product and active pharmaceutical ingredients (API) manufacturing, distribution via its global partner network, healthcare provider engagement, patient safety services, and patient access services through U.S. Market Access.

# # #

## **pharma& Media Contact:**

[media@pharmaand.com](mailto:media@pharmaand.com)